title · verified active inventory

Senior Medical Science Liaison, Lymphoma (Lacutamab) Jobs

10 verified active senior medical science liaison, lymphoma (lacutamab) jobs. Every role links to its existing canonical PAIGE job page.

Last verified: 2026-11-05 · Source: PAIGE canonical title registry
10verified active jobs
1employers
1countries
10cities

This is a directory page, not a job posting. It carries no JobPosting schema. A verified HTTP 200 job link does not independently prove that an employer is still accepting applications.

Verified active roles

Showing 10 of 10 active roles. Search all matching jobs.

RoleEmployerLocationAdvertised pay
Senior Medical Science Liaison, Lymphoma (Lacutamab)sobiDenver, us$215,000
Senior Medical Science Liaison, Lymphoma (Lacutamab)sobiRaleigh, us$215,000
Senior Medical Science Liaison, Lymphoma (Lacutamab)sobiPhoenix, us$215,000
Senior Medical Science Liaison, Lymphoma (Lacutamab)sobiLas Vegas, us$215,000
Senior Medical Science Liaison, Lymphoma (Lacutamab)sobiChicago, us$215,000
Senior Medical Science Liaison, Lymphoma (Lacutamab)sobiPhiladelphia, us$215,000
Senior Medical Science Liaison, Lymphoma (Lacutamab)sobiSan Francisco, us$215,000
Senior Medical Science Liaison, Lymphoma (Lacutamab)sobiDallas, us$215,000
Senior Medical Science Liaison, Lymphoma (Lacutamab)sobiNew York, us$215,000
Senior Medical Science Liaison, Lymphoma (Lacutamab)sobiSan Diego, us$215,000

Top employers

  • sobi (10)

Skills and qualifications

  • regulatory compliance (10)

Salary evidence

10 active jobs include advertised pay evidence. Currency and pay period are preserved as observed; no conversion, annualization or imputation was performed.

Related occupations and locations

Methodology and limitations

Records are drawn from the PAIGE canonical occupation inventory and canonical job registry. Counts are the verified active inventory observed on 2026-11-05. Salary figures are advertised/observed values, not a statistically representative survey. No vacancy, salary, skill, employer identity or translation was invented. Pages below the substantive-content threshold are not published and remain NOINDEX.